Neoadjuvant chemotherapy modifies serum angiotensinase activities in women with breast cancer

• Published in: Maturitas Vol. 72; no. 1; pp. 79 - 83
• Main Authors: Ramírez-Expósito, María Jesús, Carrera-González, María del Pilar, Mayas, María Dolores, Dueñas, Basilio, Martínez-Ferrol, Julia, Martínez-Martos, José Manuel
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01-05-2012; Elsevier
• Subjects: Aminopeptidases; Aminopeptidases - blood; Angiotensin II - analogs & derivatives; Angiotensin II - blood; Anthracyclines - pharmacology; Anthracyclines - therapeutic use; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Chemotherapy; Endopeptidases - blood; Female; Glutamyl Aminopeptidase - blood; Gynecology. Andrology. Obstetrics; Humans; Internal Medicine; Mammary gland diseases; Medical sciences; Middle Aged; Naphthalenes - blood; Neoadjuvant Therapy - methods; Obstetrics and Gynecology; Paclitaxel - pharmacology; Paclitaxel - therapeutic use; Puberal and climacteric disorders (male and female); Reference Values; Renin angiotensin system; Renin-Angiotensin System - drug effects; Tumors; angiotensin IV; RAS; Aminopeptidases; Breast cancer; renin–angiotensin system; Ang II; APA; Renin angiotensin system; Chemotherapy; aminopeptidase N; APB; aspartil aminopeptidase; angiotensin II; Ang IV; aminopeptidase A; APN; aminopeptidase B; ASAP; Human; Biological fluid; Breast disease; Enzyme; Malignant tumor; Neoadjuvant treatment; Mammary gland diseases; Peptidases; Treatment; Hydrolases; Female; Serum; Woman; Cancer
• ISSN: 0378-5122; 1873-4111
• DOI: 10.1016/j.maturitas.2012.02.007

Abstract Purpose The aim of this study was to investigate the putative changes in serum angiotensinase activities (aminopeptidase N, APN; aminopeptidase B, APB; aminopeptidase A, APA; aspartyl aminopeptidase, ASAP) involved in the renin–angiotensin system (RAS) in women with breast cancer treated or not with a neoadjuvant therapy of paclitaxel and anthracycline and in healthy women volunteers. Methods We fluorometrically analysed serum APN, APB, APA and ASAP activities using their corresponding aminoacyl-β-naphthylamides as substrates in women with breast cancer treated with a neoadjuvant therapy of paclitaxel and anthracycline. Results When compared with healthy controls, women with breast cancer not treated with neoadjuvant chemotherapy, showed a decrease in angiotensinase activity, which support the putative increase of angiotensin II (Ang II) levels, indicating that the tumour process would favour the development of the disease. Also, an increase in APN and APB activities was observed, which support a role for angiotensin IV (Ang IV). In women treated with a neoadjuvant therapy, we described an increase in ASAP and APA activities, supporting the idea that this treatment increases Ang II catabolism. The resulting decrease in Ang II level could lead to an inhibition of the tumour growth. Conclusion Present results show changes in serum angiotensinase activities in women with breast cancer and in women with breast cancer treated with a neoadjuvant therapy of paclitaxel and anthracycline. Therefore, considerable attention should be focused on the development of RAS blockade therapy as a new strategy for breast cancer treatment.